PMID- 23226738
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 4
IP  - 5
DP  - 2012 Nov
TI  - Maintenance erlotinib improves clinical outcomes of unresectable advanced 
      non-small cell lung cancer: A meta-analysis of randomized controlled trials.
PG  - 849-858
AB  - The aim of this study was to evaluate the efficacy and safety of erlotinib as 
      maintenance therapy in patients with unresectable non-small cell lung cancer 
      (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 
      patients were analyzed. Erlotinib was administered to 2,191 patients as 
      maintenance treatment, while the remaining patients received a placebo or 
      observation only. The meta-analysis was performed using Reviewer Manager Version 
      5.12 software. Compared with the control group, maintenance erlotinib improved 
      progression-free survival (PFS) and overall survival (OS) with moderate 
      heterogeneity. Results from the random effects model analysis for OS were not in 
      concordance with the difference observed in the fixed effects model analysis. 
      Administration of erlotinib only after chemotherapy obtained a higher objective 
      response rate (ORR). Safety analyses indicated a slight increase in side-effects. 
      The most common adverse events (AEs) were diarrhea and rash, which were usually 
      manageable. There was no significant difference in treatment-related deaths. 
      Erlotinib produced significant clinical benefits with acceptable toxicity as a 
      maintenance strategy in patients with unresectable NSCLC, particularly when 
      sequentially administered with chemotherapy. However, more well-designed 
      randomized control trials (RCTs) are required to identify patients that may 
      derive greater benefits from maintenance with erlotinib, and whether the use of 
      erlotinib as maintenance therapy is more efficient than second-line treatment 
      should also be investigated.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Thoracic Surgery Department and Clinical Research Center for Thoracic Oncology, 
      The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, P.R. 
      China.
FAU - Zhang, Weiqing
AU  - Zhang W
FAU - Huang, Shaohong
AU  - Huang S
FAU - Li, Hui
AU  - Li H
FAU - Li, Yun
AU  - Li Y
FAU - Chen, Huiguo
AU  - Chen H
FAU - Wu, Weibing
AU  - Wu W
FAU - Zhou, Wei
AU  - Zhou W
FAU - Wang, Cuiping
AU  - Wang C
FAU - Liao, Hongying
AU  - Liao H
FAU - Gu, Lijia
AU  - Gu L
LA  - eng
PT  - Journal Article
DEP - 20120831
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3493745
EDAT- 2012/12/12 06:00
MHDA- 2012/12/12 06:01
PMCR- 2012/08/31
CRDT- 2012/12/11 06:00
PHST- 2012/03/21 00:00 [received]
PHST- 2012/06/28 00:00 [accepted]
PHST- 2012/12/11 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2012/12/12 06:01 [medline]
PHST- 2012/08/31 00:00 [pmc-release]
AID - etm-04-05-0849 [pii]
AID - 10.3892/etm.2012.690 [doi]
PST - ppublish
SO  - Exp Ther Med. 2012 Nov;4(5):849-858. doi: 10.3892/etm.2012.690. Epub 2012 Aug 31.